- Home
- TOVX vs VTAK Comparison
TOVX vs VTAK Comparison
Compare TOVX & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- VTAK
- Stock Information
- Founded
- TOVX 2001
- VTAK 2002
- Country
- TOVX United States
- VTAK United States
- Employees
- TOVX N/A
- VTAK N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- VTAK Medical/Dental Instruments
- Sector
- TOVX Health Care
- VTAK Health Care
- Exchange
- TOVX Nasdaq
- VTAK Nasdaq
- Market Cap
- TOVX 3.8M
- VTAK 4.1M
- IPO Year
- TOVX 2006
- VTAK 2018
- Fundamental
- Price
- TOVX $0.42
- VTAK $2.60
- Analyst Decision
- TOVX Hold
- VTAK
- Analyst Count
- TOVX 1
- VTAK 0
- Target Price
- TOVX N/A
- VTAK N/A
- AVG Volume (30 Days)
- TOVX 13.2M
- VTAK 416.9K
- Earning Date
- TOVX 11-11-2025
- VTAK 11-12-2025
- Dividend Yield
- TOVX N/A
- VTAK N/A
- EPS Growth
- TOVX N/A
- VTAK N/A
- EPS
- TOVX N/A
- VTAK N/A
- Revenue
- TOVX N/A
- VTAK $600,000.00
- Revenue This Year
- TOVX N/A
- VTAK $822.86
- Revenue Next Year
- TOVX N/A
- VTAK $168.42
- P/E Ratio
- TOVX N/A
- VTAK N/A
- Revenue Growth
- TOVX N/A
- VTAK 37.62
- 52 Week Low
- TOVX $0.37
- VTAK $2.20
- 52 Week High
- TOVX $2.64
- VTAK $33.06
- Technical
- Relative Strength Index (RSI)
- TOVX 48.00
- VTAK 52.41
- Support Level
- TOVX $0.39
- VTAK $2.52
- Resistance Level
- TOVX $0.86
- VTAK $2.83
- Average True Range (ATR)
- TOVX 0.08
- VTAK 0.20
- MACD
- TOVX 0.01
- VTAK -0.01
- Stochastic Oscillator
- TOVX 6.71
- VTAK 24.68
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.